NEW YORK (GenomeWeb News) – BioTrove and Gene Express said today that they have been awarded a two-year grant from the National Cancer Institute to develop a genetic profiling test for the risk of lung cancer in collaboration with Mount Sinai School of Medicine.
The researchers will combine BioTrove’s OpenArray PCR platform, Gene Express’ PCR standards, and Mount Sinai’s clinical knowledge to study genetic biomarkers linked to lung cancer.
Funded through the NCI’s Innovative Technologies for Molecular Analysis of Cancer program, the research will aim to develop a gene expression profiling system called Standardized Nanoarray PCR, or SNAP.
The SNAP system will be based on the Gene Express Standardized RT PCR method to control for false negatives and false positives and the BioTrove OpenArray nanofluidic PCR platform, which will “enable large-scale analyses with minimal sample requirements.”
According to the companies, the resulting system “will provide the same quality and dynamic range of standard real-time quantitative PCR, but with simplified workflow and reduced sample requirements — an important consideration when dealing with limited clinical samples.”
Once the tool is developed, the companies said it will undergo an independent evaluation at the Harvard University School of Dental Medicine and at Stanford University’s Genome Technology Center.
"A real need exists for point-of-care gene expression analysis, but without standardized measurements for expression patterns, current technology cannot produce reliable results,” said Gene Express’ executive VP of corporate development, David Lester, in a statement.